Review of intraurethral suppositories and iontophoresis therapy for erectile dysfunction

International Journal of Impotence Research

Volumn 12, Issue , 2000, Pages S86-S90

  Lewis, R W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Electromotive drug delivery; International index of erectile function; Peyronie s disease; Pharmacotherapy

Indexed keywords

CORTISONE; DEXAMETHASONE; PROSTAGLANDIN E1; PROSTAVASIN;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFECT; ERECTILE DYSFUNCTION; HUMAN; IONTOPHORESIS; MALE; PENIS ERECTION; PEYRONIE DISEASE; PRIORITY JOURNAL;

ALPROSTADIL; CLINICAL TRIALS; HUMAN; IMPOTENCE; IONTOPHORESIS; MALE; PENILE INDURATION; SUPPOSITORIES; URETHRA; VASODILATOR AGENTS;

EID: 0033781302     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900584     Document Type: Article

References (18)

1. Wolfson B et al. Intraurethral prostaglandin E-2 Cream: A possible alternative treatment for erectile dysfunction. Urology 1993; 42: 73-75.
2. Lazzeri M et al. Intraurethrally infused capsaicin induces penile erection in humans. Scand J Urol Nephrol 1994; 28: 409-412.
3. Tam P et al. Hemodynamic effects of transurethral alprostadil measured by color duplex ultrasonography in men with erectile dysfunction. J Urol 1998; 160: 1321-1324.
4. Padma-Nathan H et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Engl J Med 1997; 336: 1-7.
5. Fulgham PF et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998; 160: 2041-2046.
6. McVary KT et al. Efficacy of transurethral alprostadil in patients who failed prior intracavernosal injection therapy. Int J Impot lies 1996: 8: 146, Abst D97.
7. Lewis RW, Weldon K, Nemo K. Combined use of transurethral alprostadil an adjustable penile constriction band in men with erectile dysfunction: Results from a multicenter trial. Int J Impot lies 1998; 10: S49, Abst 365.
8. Lewis RW et al. A comparison of transurethral alprostadil and alprostadil/prazosin combinations for the treatment of erectile dysfunction (ED). J Urol 1997; 159: Abst 703, 181.
9. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil — a comparative study in 103 patients with erectile dysfunction. Int J Impot lies 1997; 9: 187-192.
10. Shabsigh R et al. Intracavernous Alprostadil Alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional ACTIS: A comparative, randomized, crossover, multicenter study. Urology 2000; 55: 109-113.
11. Wong HY, Griffith DP. Iontophoresis in medicine: Possible applications in urology. Minim Inva Ther 1993; 2: 51-57.
12. Singh J, Maibach HI. Topical iontophoretic drug delivery in vivo: Historical development, devices and future perspectives. Dermatology 1993; 187: 235-238.
13. Gurpinar T, Truongld, Wong HY, Griffith DP. Electromotive drug administration to the urinary bladder: An animal model and preliminary results. J Urol 1996; 156: 1496-1501.
14. Rothfeld SH, Murray W. The treatment of Peyronie’s disease by iontophoresis of C2i esterified glucocorticoids. J Urol 1967; 97: 874-875.
15. Kahn J. Use of iontophoresis in Peyronie’s disease: A case report. Phys. Ther 1982; 62: 995-996.
16. Fishman IJ, Wong HY, Griffith DP. Case report. Iontophoretic delivery of steroids in the treatment of Peyronie’s disease: Case reports of three successful outcomes. Minim Invas Ther 1994; 3: 121-124.
17. Montorsi F et al. Transdermal electromotive multi-drug administration for Peyronie’s disease: A randomized, doubleblind, placebo-controlled, partial crossover study. J Urol 1995; 153: 472A, Abstr 973.
18. Reidl CR et al. Iontophoresis for treatment of Peyronie’s disease. J Urol 2000; 163: 95-99.